Related Experiment Video

Updated: Jun 12, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?

Jasmin Otten1, Carsten Bokemeyer, Walter Fiedler

  • 1Sections of Pneumonology and Bone Marrow Transplantation, Department of Oncology and Hematology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Journal of Oncology
|May 22, 2010
PubMed

Insights

The Transforming Growth Factor-beta (TGF-beta) pathway regulates cell functions and is implicated in cancer. Targeting this pathway offers promising therapeutic strategies for cancer treatment.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Oncology

Background:

  • The Transforming Growth Factor-beta (TGF-beta) pathway is a critical regulator of cellular processes like proliferation, differentiation, and apoptosis.
  • TGF-beta's role in tumor growth and neoangiogenesis is increasingly recognized.
  • Mutations in TGF-beta receptors are linked to vascular disorders such as Hereditary Hemorrhagic Teleangiectasia and Loeys-Dietz syndrome.

Purpose of the Study:

  • To review the multifaceted roles of the TGF-beta pathway in cellular behavior and cancer.
  • To discuss current therapeutic strategies targeting the TGF-beta pathway for cancer treatment.

Main Methods:

  • Literature review of studies on TGF-beta pathway.
  • Analysis of therapeutic approaches targeting TGF-beta receptors and ligands.
  • Examination of clinical trial data for TGF-beta pathway inhibitors.

Main Results:

  • The TGF-beta pathway influences various cell types, including tumor cells, endothelial cells, immune cells, and fibroblasts.
  • Therapeutic interventions include antisense oligonucleotides, receptor antibodies, and small molecule inhibitors.
  • An antibody targeting ALK-1 for tumor vasculature has entered clinical trials.

Conclusions:

  • The TGF-beta pathway is a significant target for cancer therapy.
  • Modulating the TGF-beta pathway presents substantial opportunities for future cancer treatment strategies.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...